Cellectar Biosciences, Inc. (CLRB) Financial Statements (2024 and earlier)

Company Profile

Business Address 100 CAMPUS DRIVE
FLORHAM PARK, NJ 07932
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments19,866,35835,703,97557,165,37710,614,72213,255,61610,006,421
Cash and cash equivalents19,866,35835,703,97557,165,37710,614,72213,255,61610,006,421
Other undisclosed current assets663,243867,485774,432770,951696,218932,996
Total current assets:20,529,60136,571,46057,939,80911,385,67313,951,83410,939,417
Noncurrent Assets
Operating lease, right-of-use asset560,334 282,365348,841
Property, plant and equipment418,641344,491355,982435,083543,339244,713
Long-term investments and receivables75,00075,00075,00075,000540,823 
Long-term investments75,00075,00075,00075,000540,823 
Intangible assets, net (including goodwill)      1,675,462
Goodwill      1,675,462
Other noncurrent assets6,2146,2146,2146,21418,08611,872
Other undisclosed noncurrent assets  204,644    
Total noncurrent assets:1,060,189630,349719,561865,1381,102,2481,932,047
TOTAL ASSETS:21,589,79037,201,80958,659,37012,250,81115,054,08212,871,464
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:5,478,4433,854,9143,443,1972,663,8731,543,8191,867,758
Employee-related liabilities504,000850,000395,000408,000 
Accounts payable 2,558,0001,415,0001,429,0001,278,000612,000 
Accrued liabilities 1,283,00055,000377,000271,000192,000 
Other undisclosed accounts payable and accrued liabilities1,637,4431,880,914787,197719,873331,8191,867,758
Debt    105,8852,2133,036
Deferred rent credit     33,090
Derivative instruments and hedges, liabilities    43,000105,050
Deferred revenue and credits138,944
Other undisclosed current liabilities50,847135,449119,904   
Total current liabilities:5,529,2903,990,3633,563,1012,769,7581,622,1222,114,788
Noncurrent Liabilities
Long-term debt and lease obligation  166,292301,740421,644 2,213
Capital lease obligations 2,213
Liabilities, other than long-term debt552,981   170,999 
Deferred rent credit     170,999
Operating lease, liability552,981166,292301,740421,644
Other undisclosed noncurrent liabilities  (166,292)(301,740)   
Total noncurrent liabilities:552,981166,292301,740421,644170,9992,213
Total liabilities:6,082,2714,156,6553,864,8413,191,4021,793,1212,117,001
Temporary equity, carrying amount      
Equity
Equity, attributable to parent, including:15,507,51933,045,15454,794,5299,059,40913,260,96110,754,463
Preferred stock1,382,023     
Common stock946114549447167
Additional paid in capital193,624,445182,560,309161,533,653119,592,366108,323,20894,107,830
Accumulated deficit(179,499,043) (126,775,427)(111,681,255)(97,588,343)(84,349,316)
Other undisclosed equity, attributable to parent  (149,515,766)20,035,8491,148,2042,526,049995,782
Total equity:15,507,51933,045,15454,794,5299,059,40913,260,96110,754,463
TOTAL LIABILITIES AND EQUITY:21,589,79037,201,80958,659,37012,250,81115,054,08212,871,464

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Gross profit:     (50,898) 
Operating expenses(28,813,773)(24,131,280)(15,290,349)(14,178,624)(13,279,866)(13,600,970)
Operating loss:(28,813,773)(24,131,280)(15,290,349)(14,178,624)(13,330,764)(13,600,970)
Nonoperating income (expense)152,5198,918196,17785,71291,73738,680
Investment income, nonoperating  6,634 43,00062,05022,075
Interest and debt expense   185,280   
Loss from continuing operations before income taxes:(28,661,254)(24,122,362)(14,908,892)(14,092,912)(13,239,027)(13,562,290)
Income tax benefit 60,000     
Other undisclosed income from continuing operations      
Loss from continuing operations:(28,601,254)(24,122,362)(14,908,892)(14,092,912)(13,239,027)(13,562,290)
Loss before gain (loss) on sale of properties:(24,122,362)(14,908,892)(14,092,912)(13,239,027)(13,562,290)
Net loss:(28,601,254)(24,122,362)(14,908,892)(14,092,912)(13,239,027)(13,562,290)
Other undisclosed net loss attributable to parent   (185,280)   
Net loss attributable to parent:(28,601,254)(24,122,362)(15,094,172)(14,092,912)(13,239,027)(13,562,290)
Preferred stock dividends and other adjustments     (2,241,795)(1,448,945)
Net loss available to common stockholders, diluted:(28,601,254)(24,122,362)(15,094,172)(14,092,912)(15,480,822)(15,011,235)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(28,601,254)(24,122,362)(14,908,892)(14,092,912)(13,239,027)(13,562,290)
Comprehensive loss, net of tax, attributable to parent:(28,601,254)(24,122,362)(14,908,892)(14,092,912)(13,239,027)(13,562,290)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: